AEON stock icon

AEON Biopharma
AEON

$1.39
2.21%
 

About: AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Employees: 10

0
Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

600% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 1

267% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 3

82% more capital invested

Capital invested by funds: $56.8M [Q4 2023] → $103M (+$46.7M) [Q1 2024]

30% more funds holding

Funds holding: 20 [Q4 2023] → 26 (+6) [Q1 2024]

2.17% more ownership

Funds ownership: 23.32% [Q4 2023] → 25.49% (+2.17%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

Research analyst outlook

We haven’t received any recent analyst ratings for AEON.

Financial journalist opinion